A simplified method for the estimation of urinary total hydroxyproline

Nobbs, B.T.; Walker, Aaron; Davies, T.G.

doi:10.1016/0009-8981(75)90206-5

Cited by 23 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intact PTH was measured by IRMA (Nichols Institute Diagnostics, San Juan Capistrano, CA, U.S.A.) with total CVs of 11.0, 7.5, and 6.5% at serum concentration of 13.5, 43.1, and 186 ng/l, respectively. Urine hydroxyproline was measured as described previously 39 . Serum and urine calcium was measured by absorption spectrophotometry (Boehringer Mannheim, Mannheim, Germany).…”

Section: Methodsmentioning

confidence: 99%

Treatment with the Oral Growth Hormone Secretagogue MK-677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males

Svensson

Ohlsson

Jansson

et al. 1998

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Treatment with the Oral Growth Hormone Secretagogue MK-677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males

Svensson

Ohlsson

Jansson

et al. 1998

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

show abstract

“…Urinary cAMP was assayed according to the method of Steiner et al [14], using antisera developed in the rabbit. Urine hydroxyproline excretion was determined colorimetrically [15].…”

Section: Methodsmentioning

confidence: 99%

The hypercalcemic rat leydig cell tumor—A model of the humoral hypercalcemia of malignancy

et al. 1983

View full text Add to dashboard Cite

Summary. A transplantable nonmetastasizingLeydig cell tumor, which occurs spontaneously in the aged Fischer rat, was examined both in vitro and in vivo. Animals carrying this tumor were found to have the syndrome recently called the humoral hypercalcemia of malignancy, characterized by hypercalcemia, hypercalciuria, hypophosphatemia, renal phosphate wasting, increased urinary 3'5'-cyclic monophosphate (cyclic AMP) excretion, and suppressed circulating parathyroid hormone (PTH) concentrations. The changes in urinary cyclic adenosine monophosphate (cAMP) excretion occurred simultaneously with hypercalcemia in most animals. In one animal, the primary tumor was excised and this was followed by an immediate fall in serum calcium and urine cAMP excretion. Hypercalcemia was due to increased bone resorption. This was shown by bone histology, which demonstrated an increase in osteoclast number and activity on trabecular bone surfaces associated with bone loss in tumor-bearing animals. No tumor cells were seen adjacent to the osteoclasts. There was no evidence of metastatic disease as assessed by bone-seeking isotopes. Urinary hydroxyproline excretion was increased in tumor-bearing hypercalcemic animals, indicating an increase in bone turnover. The tumor cells were established in culture and found to produce a bone-resorbing factor in vitro using a bioassay for bone resorption based on the release of previously incorporated 4~Ca from fetal rat long bones in culture. This model of the humoral hypercalcemia of malignancy should make it possible to determine the nature of the boneresorbing factor produced by the cultured tumor cells which is responsible for the hypercalcemia, and the relationship of hypercalcemia and the production of the bone-resorbing factor to the other Send offprint requests to G. R. Mundy at the above address.parameters of the syndrome, namely, renal phosphate wasting and increased urinary cAMP excretion.

show abstract

“…Urinary cyclic AMP was assayed according to the Steiner et al method [16]. Urine hydroxyproline was assessed by the Nobels et al method [17].…”

Section: Methodsmentioning

confidence: 99%

The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat leydig cell tumor

et al. 1983

View full text Add to dashboard Cite

Summary. There is a high frequency of Leydig cell tumors associated with hypercalcemia in the aged Fischer 344 rat. We studied a transplantable tumor cell line (Rice D-6) which is associated with hypercalcemia, hypercalciuria, hypophosphatemia, renal phosphate wasting, increased urinary cyclic adenosine monophosphate (AMP) excretion, absence of bone metastases, increased osteoclastic bone resorption, and suppressed immunoreactive parathyroid hormone (iPTH) concentrations. We examined the ability of dichloromethylene diphosphonate (CI2MDP) to lower serum calcium and decrease the parameters of increased bone resorption. We used this drug also as a pharmacologic tool to determine the relationship of hypercalcemia and increased bone resorption to the abnormalities in renal tubular function associated with the humoral hypercalcemia of malignancy.Daily administration of CI.,MDP before development of hypercalcemia, in doses from 2.5-40 mg/kg body weight subcutaneously, delayed and suppressed both the hypercalcemia and hypercalciuria. There was an increase in bone mass and decrease in both osteoclast number and activity compared with bones from untreated tumor-bearing animals. The urinary hydroxyproline excretion in treated animals declined towards the normal range. There were no significant effects on serum phosphorus, urine phosphorus, or urine cyclic AMP excretion.These data suggest that C12MDP reverses the increased bone resorption that occurs in the humoral hypercalcemia of malignancy, and confirms that diphosphonates are effective agents in the prevention and treatment of increased bone resorption associated with malignant disease. They also suggest Send offprint requests to Dr. Martodam at the above address.that renal phosphate wasting and increased urinary cyclic AMP excretion are not directly related to the hypercalcemia.

show abstract

A simplified method for the estimation of urinary total hydroxyproline

Cited by 23 publications

References 3 publications

Treatment with the Oral Growth Hormone Secretagogue MK-677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males

Treatment with the Oral Growth Hormone Secretagogue MK-677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males

The hypercalcemic rat leydig cell tumor—A model of the humoral hypercalcemia of malignancy

The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat leydig cell tumor

Contact Info

Product

Resources

About